Table 1.

First line treatment with DAAs by genotype (Gt), version of introduction protocol and stage of fibrosis (F)

	2014-11-07 (2.0)	2015-01-12 (3.0)	2015-03-06 (4.0)	2015-04-13 (5.0)	2015-07-02 (6.0)
Gt 1	F3–F4 SOF + SIM	F3–F4 Treatment naïve: SOF + SIM Previously treated: SOF + SIM or SOF + DAC	F3–F4 SOF/LED	F3–F4 SOF/LED or OMB/PAR/RIT + DAS	F3–F4 SOF/LED or OMB/PAR/RIT + DAS F2 SOF/LED
Gt 2	F3–F4 SOF + ribavirin	F3–F4 SOF + ribavirin	F3–F4 SOF + ribavirin	F3–F4 SOF + ribavirin	F2–F4 SOF + ribavirin
Gt 3	F3–F4	F3–F4 SOF + DAC	F3–F4 SOF + DAC or SOF/LED	F3–F4 SOF + DAC or SOF/LED	F3–F4 SOF + DAC or SOF + ribavirin F2 SOF + ribavirin
Gt 4	F3–F4 SOF + SIM	F3–F4 Treatment naïve: SOF + SIM Previously treated: SOF + SIM or SOF + DAC	F3–F4 SOF/LED	F3–F4 OMB/PAR/RIT + ribavirin	F3–F4 SOF/LED or OMB/PAR/RIT + ribavirin F2 SOF/LED

Ribavirin could be added where suitable. Treatment duration (varying with disease severity) is not presented here. Previous treatment status refers to previous use of telaprevir and boceprevir

SOF sofosbuvir, SIM simeprevir, DAC daclatasvir, SOF/LED sofosbuvir/ledipasvir, DAS dasabuvir, PAR/OMB/RIT paritaprevir/ombitasvir/ritonavir